Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes

Nature Nanotechnology

Volumn 12, Issue 6, 2017, Pages 589-594

  Wibroe, Peter Popp ^a   Anselmo, Aaron C ^b   Nilsson, Per H ^c,d,e   Sarode, Apoorva ^b   Gupta, Vivek ^f   Urbanics, Rudolf ^g   Szebeni, Janos ^g   Hunter, Alan Christy ^h   Mitragotri, Samir ^b   Mollnes, Tom Eirik ^c,d,i,j,k   Moghimi, Seyed Moein ^a,l,m  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of California   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e LINNAEUS UNIVERSITY   (Sweden)

^f ST JOHN'S UNIVERSITY   (United States)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h DE MONTFORT UNIVERSITY   (United Kingdom)

ⁱ NORDLAND HOSPITAL   (Norway)

^j UNIVERSITY OF TROMSØ   (Norway)

^k NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m DURHAM UNIVERSITY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; MACROPHAGES; MAMMALS; MORPHOLOGY; POLYETHYLENE GLYCOLS;

COMPLEMENT ACTIVATIONS; COMPLEMENT SYSTEMS; NANOPARTICLE SURFACE; NANOPHARMACEUTICALS; PARTICLE GEOMETRIES; PARTICLE RECOGNITION; PEGYLATED NANOPARTICLE; SHAPE MODIFICATION;

NANOPARTICLES;

MACROGOL; NANOPARTICLE;

ANIMAL CELL; ARTICLE; BIOENGINEERING; CARDIOPULMONARY DISTRESS; CELL ADHESION; CELL SURFACE; CHEMICAL STRUCTURE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LUNG CLEARANCE; MACROPHAGE; MOLECULAR RECOGNITION; NONHUMAN; PARTICLE SIZE; PIG; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SURFACE PROPERTY; ANIMAL; CHEMISTRY; DRUG EFFECT; METABOLISM;

ANIMALS; COMPLEMENT ACTIVATION; ERYTHROCYTES; HUMANS; MACROPHAGES; NANOPARTICLES; POLYETHYLENE GLYCOLS; SWINE;

EID: 85017261848     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2017.47     Document Type: Article

References (51)

1. Kattan, J. et al. Phase, I. Clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest. New Drugs 10, 191-199 (1992).
2. Laing, R. B., Milne, L. J., Leen, C. L., Malcolm, G. P. & Steers, A. J. Anaphylactic reactions to liposomal amphotericin. Lancet 344, 682 (1994).
3. Uziely, B. et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13, 1777-1785 (1995).
4. Moghimi, S. M., Wibroe, P. P., Helvig, S. Y., Farhangrazi, Z. S. & Hunter, A. C. Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward. Adv. Drug Deliver. Rev. 64, 1385-1393 (2012).
5. Szebeni, J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol. Immunol. 61, 163-173 (2014).
6. Kastl, S. P. et al. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler. Thromb. Vasc. Biol. 28, 498-503 (2008).
7. Woodruff, T. M., Nandakumar, K. S. & Tedesco, F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48, 1631-1642 (2011).
8. Szebeni, J. et al. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv. Drug Deliv. Rev. 64, 1706-1716 (2012).
9. Szebeni, J. et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 290, H1050-H1058 (2006).
10. Warner, A. E. Pulmonary intravascular macrophages. role in acute lung injury. Clin. Chest Med. 17, 125-135 (1996).
11. Schneberger, D., Aharonson-Raz, K. & Singh, B. Pulmonary intravascular macrophages and lung health: what are we missing? Am. J. Physiol. Lung Cell Mol. Physiol. 302, L498-L503 (2012).
12. Longworth, K. E., Westgate, A. M., Grady, M. K., Westcott, J. Y. & Staub, N. C. Development of pulmonary intravascular macrophage function in newborn lambs. J. Appl. Physiol. 73, 2608-2615 (1992).
13. Csuks, D., Urbanics, R., Wber, G., Rosivall, L. & Szebeni, J. Pulmonary intravascular macrophages: prime suspects as cellular mediators of porcine CARPA. Eur. J. Nanomed. 7, 27-36 (2015).
14. Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228-236 (2007).
15. Moghimi, S. M. Complement propriety and conspiracy in nanomedicine: perspective and a hypothesis. Nucleic Acid Ther. 26, 67-72 (2016).
16. Keyes, J.W. Jr, Wilson, G. A. & Quinonest, J. D. An evaluation of lung uptake of colloid during liver imaging. J. Nucl. Med. 14, 687-691 (1973).
17. Imarisio, J. J. Liver scan showing intense lung uptake in neoplasia and infection. J. Nucl. Med. 16, 188-190 (1975).
18. Moghimi, S. M. et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 146, 175-181 (2010).
19. Chanan-Khan, A. et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430-1437 (2003).
20. Szebeni, J. et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine 8, 176-184 (2012).
21. Moghimi, S. M., Hamad, I., Andresen, T. L., Jorgensen, K. & Szebeni, J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20, 2591-2593 (2006).
22. Andersen, A. J. et al. Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano. 7, 1108-1119 (2013).
23. Moghimi, S. M. & Murray, J. C. Poloxamer-188 revisited: a potentially valuable immune modulator? J. Natl Cancer Inst. 88, 766-768 (1996).
24. Laverman, P., Carstens, M. G., Storm, G. & Moghimi, S. M. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim. Biophys. Acta 1526, 227-229 (2001).
25. Kolhar, P. et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl Acad. Sci. USA 110, 10753-10758 (2013).
26. Lu, Z. S., Qiao, Y., Zheng, X. T., Chan-Park, M. B. & Li, C. M. Effect of particle shape on phagocytosis of CdTe quantum dot-cystine composites. MedChemComm 1, 84-86 (2010).
27. Champion, J. A. & Mitragotri, S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103, 4930-4934 (2006).
28. Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotech. 2, 249-255 (2007).
29. Chambers, E. & Mitragotri, S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J. Control. Release, 100, 111-119 (2004).
30. Anselmo, A. C. et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7, 11129-11137 (2013).
31. Moghimi, S. M., Hunter, A. C. & Andresen, T. L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 52, 481-503 (2012).
32. Jansen, J. H., Hogasen, K. & Mollnes, T. E. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am. J. Pathol. 143, 1356-1365 (1993).
33. Wibroe, P. P., Ahmadvand, D., Oghabian, M. A., Yaghmur, A. & Moghimi, S. M. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil, Caelyx, DOXOrubicin, and SinaDoxosome. J. Control. Release 221, 1-8 (2016).
34. Hamad, I. et al. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4, 6629-6638 (2010).
35. Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotech. http://dx.doi.org/10.1038/ nnano.2016.269 (2016).
36. Montalescot, G. et al. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 84, 2054-2062 (1991).
37. Gaca, J. G. et al. Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. J. Surg. Res. 112, 19-25 (2003).
38. Szebeni, J. et al. The role of complement activation in hypersensitivity to PEGylated liposomal doxorubicin (Doxil). J. Liposome Res. 10, 467-481 (2000).
39. Sone, Y., Serikov, V. B. & Staub, N. C. Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. J. Appl. Physiol. 87, 1354-1359.
40. Decuzzi, P. et al. Size and shape effects in the biodistribution of intravascularly injected particles. J. Control. Release 141, 320-327 (2010).
41. Decuzzi, P., Lee, S., Bhushan, B. & Ferrari, M. A theoretical model for the margination of particles with blood vessels. Ann. Biomed. Eng. 33, 179-190 (2005).
42. Castells, M. Desensitization for drug allergy. Curr. Opin. Allergy Clin. Immunol. 6, 476-481 (2006).
43. Bugna, S. et al. Surprising lack of liposome-induced complement activation by artificial 1,3-diamidophospholipids in vitro. Nanomedicine 12, 845-849 (2016).
44. Moghimi, S. M. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anticancer Agents Med. Chem. 6, 553-561 (2006).
45. Szebeni, J. et al. Hemodynamic changes induced by liposomes and liposomeencapsulated hemoglobin in pigs: a model of pseudollargic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99, 2302-2309 (1999).
46. Meszaros, T. et al. Factor H inhibits complement activation induced by liposomal and micellar drugs and the therapeutic antibody rituximab in vitro. Nanomedicine 12, 1023-1031 (2016).
47. Wu, Y. Q. et al. Protection of nonself surfaces from complement attack by factor H-binding peptides: implications for therapeutic medicine. J. Immunol. 186, 4269-4277 (2011).
48. Rodriguez, P. L. et al. Minimal self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013).
49. Perry, J. L., Herlihy, K. P., Napier, M. E. & Desimone, J. M. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 44, 990-998 (2011).
50. Mollnes, T. E. et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100, 1869-1877 (2002).
51. Bergseth, G. et al. An international serum standard for application in assays to detect human complement activation products. Mol. Immunol. 56, 232-239 (2013).